The global hypercholesterolemia market size reached US$ 17.7 Billion in 2023. Looking forward, the market is projected to reach US$ 58.2 Billion by 2032, exhibiting a growth rate (CAGR) of 14.14% during 2023-2032. Rising health consciousness, increasing geriatric population, and extensive research and development (R&D) activities represent some of the key factors driving the market growth.
Hypercholesterolemia is a lipid disorder known for an excess of low-density lipoprotein (LDL) in the blood. Some of the common conditions that lead to hypercholesterolemia are diabetes, polycystic ovary syndrome, underactive thyroid gland, and kidney diseases. It is a long-term condition, and chest pain, shortness of breath, extreme fatigue, and muscle weakness are some of the most common symptoms.
Hypercholesterolemia is a serious life-threatening ailment wherein drugs are used to decrease the level of bad cholesterol in the blood while reducing the liver’s production of harmful cholesterol. These drugs help stabilize the plaques on blood vessel walls and reduce the risk of certain blood clots. They also reduce the risk of a heart attack or stroke and dysfunction in the blood vessels.
Along with this, the introduction of various drugs and therapies to achieve near-normal lipid profiles in hypercholesterolemia patients and reduce the risk of CVDs occurrence in patients is providing a considerable boost to the market growth. Apart from this, the development of novel drug classes with enhanced efficacy and safety profile is providing an impetus to the market growth. Additionally, the launch of various combination therapies with other cholesterol-diminishing compounds to treat hypercholesterolemia is positively influencing the market growth.
Besides this, the widespread adoption of statins due to their several advantages, such as enhanced endothelial function, decreased oxidative stress-induced cell damage, increased atherosclerotic plaque stability, and reduced inflammation is facilitating the market growth. Other factors, including overall improvements in the healthcare infrastructure, extensive research, and development (R&D) activities for developing novel drugs, and the increasing number of familial hypercholesterolemia patients, are anticipated to drive the market growth.
Hypercholesterolemia is a lipid disorder known for an excess of low-density lipoprotein (LDL) in the blood. Some of the common conditions that lead to hypercholesterolemia are diabetes, polycystic ovary syndrome, underactive thyroid gland, and kidney diseases. It is a long-term condition, and chest pain, shortness of breath, extreme fatigue, and muscle weakness are some of the most common symptoms.
Hypercholesterolemia is a serious life-threatening ailment wherein drugs are used to decrease the level of bad cholesterol in the blood while reducing the liver’s production of harmful cholesterol. These drugs help stabilize the plaques on blood vessel walls and reduce the risk of certain blood clots. They also reduce the risk of a heart attack or stroke and dysfunction in the blood vessels.
Hypercholesterolemia Market Trends
The growing prevalence of hypercholesterolemia due to the rising unhealthy lifestyle among the masses is one of the key factors driving the market growth. In line with this, the increasing geriatric population that is susceptible to cardiovascular disorders (CVDs) and various other chronic diseases, such as diabetes, kidney complications, and thyroid problems, is favoring the market growth. Moreover, the rising health consciousness and the increasing awareness regarding the available treatment alternatives for hypercholesterolemia are acting as other growth-inducing factors.Along with this, the introduction of various drugs and therapies to achieve near-normal lipid profiles in hypercholesterolemia patients and reduce the risk of CVDs occurrence in patients is providing a considerable boost to the market growth. Apart from this, the development of novel drug classes with enhanced efficacy and safety profile is providing an impetus to the market growth. Additionally, the launch of various combination therapies with other cholesterol-diminishing compounds to treat hypercholesterolemia is positively influencing the market growth.
Besides this, the widespread adoption of statins due to their several advantages, such as enhanced endothelial function, decreased oxidative stress-induced cell damage, increased atherosclerotic plaque stability, and reduced inflammation is facilitating the market growth. Other factors, including overall improvements in the healthcare infrastructure, extensive research, and development (R&D) activities for developing novel drugs, and the increasing number of familial hypercholesterolemia patients, are anticipated to drive the market growth.
Key Market Segmentation
This report provides an analysis of the key trends in each segment of the global hypercholesterolemia market, along with forecasts at the global, regional, and country level from 2024-2032. The report has categorized the market based on type, diagnosis and treatment, patient, and end user.Type Insights:
- Type 1
- Type 2A
- Type 2B
- Type 3
- Type 4
- Type 5
- Others
Diagnosis and Treatment Insights:
- Diagnosis
- Cholesterol Test
- Genetic Testing
- Treatment
- Statins
- Niacin
- Bile Acid Resins
- Fibric Acid Derivatives
- Cholesterol Absorption Inhibitors
- PCSK9 Inhibitors
- Others
Patient Insights:
- Pediatric
- Adults
- Geriatric
End User Insights:
- Hospitals
- Specialty Clinics
- Home Healthcare
- Others
Regional Insights:
- North America
- United States
- Canada
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
Competitive Landscape
The report has also provided a comprehensive analysis of the competitive landscape in the global hypercholesterolemia market. Detailed profiles of all major companies have also been provided. Some of the companies covered include Amgen Inc., Dr. Reddy's Laboratories, Lupin Limited, Novartis AG, Regeneron Pharmaceuticals, Inc., etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.Key Questions Answered in This Report
- How has the global hypercholesterolemia market performed so far and how will it perform in the coming years?
- What are the drivers, restraints, and opportunities in the global hypercholesterolemia market?
- What are the key regional markets?
- Which countries represent the most attractive hypercholesterolemia markets?
- What is the breakup of the market based on the type?
- What is the breakup of the market based on the diagnosis and treatment?
- What is the breakup of the market based on patient?
- What is the breakup of the market based on the end user?
- What is the competitive structure of the global hypercholesterolemia market?
- Who are the key players/companies in the global hypercholesterolemia market?
Table of Contents
1 Preface3 Executive Summary12 Value Chain Analysis14 Price Analysis
2 Scope and Methodology
4 Introduction
5 Global Hypercholesterolemia Market
6 Market Breakup by Type
7 Market Breakup by Diagnosis & Treatment
8 Market Breakup by Patient
9 Market Breakup by End User
10 Market Breakup by Region
11 Drivers, Restraints, and Opportunities
13 Porters Five Forces Analysis
15 Competitive Landscape
List of Figures
List of Tables
Companies Mentioned
- Amgen Inc.
- Dr. Reddy's Laboratories
- Lupin Limited
- Novartis AG
- Regeneron Pharmaceuticals Inc.
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 138 |
| Published | April 2024 |
| Forecast Period | 2023 - 2032 |
| Estimated Market Value ( USD | $ 17.7 Billion |
| Forecasted Market Value ( USD | $ 58.2 Billion |
| Compound Annual Growth Rate | 14.1% |
| Regions Covered | Global |
| No. of Companies Mentioned | 5 |
